JAN
Janus Living, Inc.NYSEREAL ESTATEREIT - RESIDENTIAL
Key Statistics
Market Cap
$5.00B
P/E Ratio
—
EPS
$-0.36
Beta
—
52W High
$28.52
52W Low
$22.76
50-Day MA
$25.24
200-Day MA
$25.24
Dividend Yield
—
Profit Margin
-0.01%
Forward P/E
—
PEG Ratio
—
About Janus Living, Inc.
JanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for pain management. The company is headquartered in Las Vegas, Nevada.
Fundamentals
| Revenue (TTM) | $655.41M |
| Gross Profit (TTM) | $198.46M |
| EBITDA | $161.82M |
| Operating Margin | 0.53% |
| Return on Equity | 0.49% |
| Return on Assets | 0.48% |
| Revenue/Share (TTM) | $3.50 |
| Book Value | $11.56 |
| Price-to-Book | 2.31 |
| Price-to-Sales (TTM) | 7.63 |
| EV/Revenue | 6.19 |
| EV/EBITDA | 19.61 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 34.50% |
| Shares Outstanding | $187.22M |
| Float | $48.15M |
| % Insiders | 74.31% |
| % Institutions | 28.30% |
Analyst Ratings
Consensus ($28.91 target)
6
Strong Buy4
Buy1
HoldMore REAL ESTATE Stocks
Data last updated: 5/25/2026